These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

873 related items for PubMed ID: 24529288

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M, Bertram D.
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [Abstract] [Full Text] [Related]

  • 3. Do the European Medicines Agency Decisions Hurt Pediatric Melanoma Patients?
    Rose K, Walson PD.
    Clin Ther; 2017 Feb; 39(2):253-265. PubMed ID: 28159363
    [Abstract] [Full Text] [Related]

  • 4. The economics of pediatric formulation development for off-patent drugs.
    Milne CP, Bruss JB.
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [Abstract] [Full Text] [Related]

  • 5. The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemia.
    Rose K, Walson PD.
    Risk Manag Healthc Policy; 2015 Nov; 8():185-205. PubMed ID: 26604845
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Juvenile animal studies and pediatric drug development: a European regulatory perspective.
    Carleer J, Karres J.
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):254-60. PubMed ID: 21638754
    [Abstract] [Full Text] [Related]

  • 9. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
    Rose K, Senn S.
    Pharm Stat; 2014 Aug; 13(4):211-3. PubMed ID: 24903307
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. More than 5 years of European Paediatric Regulation: statistics and industrial experience.
    Winzenburg G.
    Int J Pharm; 2014 Aug 05; 469(2):260-2. PubMed ID: 24704106
    [Abstract] [Full Text] [Related]

  • 12. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
    Barry E, Walsh JA, Weinrich SL, Beaupre D, Blasi E, Arenson DR, Jacobs IA.
    Paediatr Drugs; 2021 Jul 05; 23(4):381-394. PubMed ID: 34173206
    [Abstract] [Full Text] [Related]

  • 13. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
    Tomasi PA, Egger GF, Pallidis C, Saint-Raymond A.
    Paediatr Drugs; 2017 Dec 05; 19(6):505-513. PubMed ID: 28900869
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.
    Ruperto N, Vesely R, Saint-Raymond A, Martini A, Paediatric Rheumatology International Trials Organisation (PRINTO).
    Ann Rheum Dis; 2013 Dec 05; 72(12):1893-6. PubMed ID: 23962457
    [Abstract] [Full Text] [Related]

  • 16. Drug development for children: how is pharma tackling an unmet need?
    Hawcutt DB, Smyth RL.
    IDrugs; 2008 Jul 05; 11(7):502-7. PubMed ID: 18600597
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Progress review of the European Paediatric Regulatory Framework after six years of implementation.
    Mentzer D.
    Int J Pharm; 2014 Aug 05; 469(2):240-3. PubMed ID: 24613178
    [Abstract] [Full Text] [Related]

  • 19. Integration of pediatric aspects into the general drug development process.
    Rose K.
    Ernst Schering Res Found Workshop; 2007 Aug 05; (59):123-34. PubMed ID: 17117719
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.